Blood Glucose Control

Managing post-meal glucose levels plays a critical role in diabetes care, yet it is often overlooked in favor of A1C and time in range. However, what happens after meals can significantly affect long-term outcomes. Think of it like traffic flow: even if the highway looks clear overall, sudden congestion at …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …

Rapid glycemic improvement with GLP-1 therapy is one of the most powerful benefits of modern diabetes care, but it can also create new clinical challenges. When glucose levels drop quickly, patients may face an increased risk of hypoglycemia if other medications are not adjusted in time. So, how do clinicians …

Why do so many patients begin treatment with good intentions, only to fall off track later? Staying consistent with diabetes treatment continues to challenge both patients and clinicians despite medical advances. While new therapies offer better control, long-term success still depends on consistency. However, many patients struggle to maintain routines, …

When managing diabetes, most people focus on A1C or time in range. However, what if the real opportunity lies in something more immediate and actionable? Managing post-meal blood sugar, often called postprandial glucose control, may hold the key to better outcomes. While long-term markers still matter, post-meal spikes often go …

Diabetic ketoacidosis remains one of the most serious complications of diabetes, yet managing it often relies on intermittent data points. What if clinicians could see ketone levels change in real time instead of waiting hours between lab tests? Continuous ketone monitoring for DKA is now emerging as a promising concept …

Can a therapy improve metabolic health even if the scale does not budge? This question is becoming increasingly relevant as clinicians observe patients benefiting from GLP-1 therapy even without significant weight loss. While weight reduction has long been a primary goal of incretin-based therapies, emerging data suggest that metabolic improvements …

Managing hyperglycemia in oncology patients is becoming a critical part of cancer care, especially as newer therapies affect glucose metabolism. Have you ever wondered why patients with no history of diabetes suddenly develop high blood sugar during treatment? This growing challenge highlights the need for structured, practical approaches. In this …

When diabetes metric discordance shows up in clinical practice, it can feel like trying to read three clocks that all tell different times. A1C suggests one story, continuous glucose monitoring points to another, and patient symptoms may not match either. So how should clinicians respond when these signals conflict? Understanding …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …